{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:22:11Z","timestamp":1781522531836,"version":"3.54.1"},"reference-count":16,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>Ravulizumab is a very expensive complement C5\u2010inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria, with a fixed\u2010dosing interval of 8 weeks. For lifelong treatment, a cost\u2010effective and patient\u2010friendly dosing strategy is preferred. We therefore explored alternative ravulizumab dosing regimens <jats:italic>in silico<\/jats:italic> based on the thorough dose\u2010finding studies of the manufacturer. Extending the interval to 10 weeks or individually extending the interval to a mean of 12.8 weeks based on pharmacokinetic monitoring resulted in noninferior efficacy in terms of lactate dehydrogenase normalization, with drug cost savings up to 37%. We here show the potential of individualized ravulizumab dosing to improve patient\u2010friendliness at reduced costs.<\/jats:p>","DOI":"10.1111\/bcp.14748","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T13:33:32Z","timestamp":1611927212000},"page":"3359-3363","source":"Crossref","is-referenced-by-count":8,"title":["The potential of individualized dosing of ravulizumab to improve patient\u2010friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-4919","authenticated-orcid":false,"given":"Mendy","family":"ter Avest","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Radboud Institute for Health Sciences Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia M.C.","family":"Langemeijer","sequence":"additional","affiliation":[{"name":"Department of Hematology Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia E.M.","family":"Schols","sequence":"additional","affiliation":[{"name":"Department of Hematology Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-2818","authenticated-orcid":false,"given":"David M.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud Institute for Health Sciences Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.A.J.","family":"van de Kar","sequence":"additional","affiliation":[{"name":"Deparment of Pediatric Nephrology Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.A.","family":"Blijlevens","sequence":"additional","affiliation":[{"name":"Department of Hematology Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wietske","family":"Kievit","sequence":"additional","affiliation":[{"name":"Department for Health Evidence Radboud University Medical Centre  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-8201","authenticated-orcid":false,"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud Institute for Health Sciences Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Ultomiris assessment report EMA\/CHMP\/220699\/2019. In 2019."},{"key":"e_1_2_9_3_1","unstructured":"BLA Multi\u2010Disciplinary Review and Evaluation BLA 761108 \u2010 Ultomiris (ravulizumab). In 2018."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876805"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","unstructured":"SahelijoL MujeebuddinA MitchellD et al.First in human single\u2010ascending dose study: safety biomarker pharmacokinetics and exposure\u2010response relationships of ALXN1210 a humanized monoclonal antibody to C5 with marked half\u2010life extension and potential for significantly longer dosing intervals. In: American Society of Hematology Washington DC 2015.","DOI":"10.1182\/blood.V126.23.4777.4777"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12347"},{"key":"e_1_2_9_9_1","first-page":"15","article-title":"Orphan drug pricing and payer management in the United States: are we approaching the tipping point?","volume":"3","author":"Hyde R","year":"2010","journal-title":"American Health & Drug Benefits"},{"key":"e_1_2_9_10_1","unstructured":"Reuters.FDA approves Alexion's Ultomiris for another rare blood disease. In 2019."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13411"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01157"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16711"},{"key":"e_1_2_9_14_1","unstructured":"Centers for Disease Control and Prevention (CDC).National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville MD: U.S. Department of Health and Human Services Centers for Disease Control and Prevention."},{"key":"e_1_2_9_15_1","unstructured":"Security and exchange commission 8\u2010K filing on wholesale acquisition cost for ULTOMIRIS. In 2018."},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","DOI":"10.3310\/hta20830","volume-title":"Clinical effectiveness and cost\u2010effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF\u2010\u03b1) inhibitors [LISA\u2010TRACKER\u00ae enzyme\u2010linked immunosorbent assay (ELISA) kits, TNF\u2010\u03b1\u2010Blocker ELISA kits and Promonitor\u00ae ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling","author":"Freeman K","year":"2016"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14747"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14748","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14748","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:14:49Z","timestamp":1693354489000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1111\/bcp.14748"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14748","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]}}}